Xenon Pharmaceuticals Inc.

As of June 30, 2026, Xenon Pharmaceuticals Inc. carries a market capitalization of 5.13B, placing it among publicly traded companies globally. Its enterprise value stands at 4.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xenon Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Xenon Pharmaceuticals Inc. has 96.75M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Xenon Pharmaceuticals Inc. maintains a current ratio of 21.02, meaning it holds 21.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Xenon Pharmaceuticals Inc. posted a negative return on equity (ROE) of -43.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -41.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 359.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Xenon Pharmaceuticals Inc. recorded an income tax benefit of -1.70M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -359.87M and -358.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Xenon Pharmaceuticals Inc.'s stock has declined approximately 10.99% over the past 52 weeks. The 50-day moving average sits at 42.01, while the 200-day moving average is 45.46.

Over the twelve months ended June 30, 2026, Xenon Pharmaceuticals Inc. generated - - in revenue and converted that into -358.17M in net income, yielding earnings per share of -4.14. EBITDA reached -384.42M, while operating income came in at -386.52M.

As of June 30, 2026, Xenon Pharmaceuticals Inc. holds 814.63M in cash and equivalents against 5.62M in total debt, resulting in a net debt position of -104.62M. Total book value stands at 1.09B, with working capital of 788.52M providing operational flexibility.

Xenon Pharmaceuticals Inc. produced -295.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -881,427.10 in capital expenditures, free cash flow totaled -296.31M - equivalent to -3.42 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.37, meaning Xenon Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Xenon Pharmaceuticals Inc. has an Altman Z-Score of 63.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.